Credit Suisse analyst Alethia Young raised her price target on Sarepta Therapeutics to $100 from $81, citing accelerated approval potential on golodirsen and her increasing excitement around upcoming initial gene therapy data around mid-2018. In a research note to investors, Young called the accelerated approval potential from the FDA for golodirsen was a "pleasant Monday morning surprise," adding that the update was a "surprise positive since we were cautiously optimistic," and now puts the probability of success at 75% from 40%. Young, who has an Outperform rating on Sarepta, said the stock is a top 2018 pick for Credit Suisse's franchise.